Replimune Group Past Earnings Performance
Past criteria checks 0/6
Replimune Group's earnings have been declining at an average annual rate of -36.7%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-36.7%
Earnings growth rate
-19.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -49.8% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Feb 06
Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer
Jan 23Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)
Dec 25Is Replimune Group (NASDAQ:REPL) A Risky Investment?
Jul 13Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?
Apr 05A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Jan 06Replimune secures $200M term loan
Oct 07Replimune: Recent Developments Strengthen Bull Thesis
Aug 12Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Aug 06Replimune Group GAAP EPS of -$0.78 misses by $0.15
Aug 04Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate
Jun 24We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate
Apr 04Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth
Dec 16Replimune: In The 'Buy Zone' Again
Oct 01Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Sep 02Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business
May 24Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic
Apr 30We're Interested To See How Replimune Group (NASDAQ:REPL) Uses Its Cash Hoard To Grow
Feb 08Replimune Group EPS misses by $0.03
Feb 04Dosing underway in Replimune's early-stage cancer study with gene therapy
Jan 05Replimune: Interesting Developer Of Oncolytic Immunotherapies
Dec 06Replimune Group EPS misses by $0.02
Nov 05Revenue & Expenses BreakdownBeta
How Replimune Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -210 | 59 | 167 |
| 30 Sep 23 | 0 | -199 | 57 | 155 |
| 30 Jun 23 | 0 | -182 | 55 | 134 |
| 31 Mar 23 | 0 | -174 | 51 | 123 |
| 31 Dec 22 | 0 | -157 | 46 | 107 |
| 30 Sep 22 | 0 | -147 | 45 | 96 |
| 30 Jun 22 | 0 | -133 | 42 | 87 |
| 31 Mar 22 | 0 | -118 | 39 | 76 |
| 31 Dec 21 | 0 | -108 | 35 | 71 |
| 30 Sep 21 | 0 | -100 | 31 | 66 |
| 30 Jun 21 | 0 | -91 | 27 | 60 |
| 31 Mar 21 | 0 | -81 | 24 | 54 |
| 31 Dec 20 | 0 | -75 | 23 | 48 |
| 30 Sep 20 | 0 | -70 | 21 | 46 |
| 30 Jun 20 | 0 | -61 | 20 | 40 |
| 31 Mar 20 | 0 | -53 | 17 | 36 |
| 31 Dec 19 | 0 | -43 | 15 | 30 |
| 30 Sep 19 | 0 | -35 | 12 | 25 |
| 30 Jun 19 | 0 | -30 | 10 | 23 |
| 31 Mar 19 | 0 | -31 | 9 | 20 |
| 31 Dec 18 | 0 | -31 | 9 | 19 |
| 30 Sep 18 | 0 | -28 | 8 | 15 |
| 30 Jun 18 | 0 | -26 | 7 | 13 |
| 31 Mar 18 | 0 | -20 | 6 | 11 |
| 31 Dec 17 | 0 | -17 | 4 | 9 |
Quality Earnings: REPL is currently unprofitable.
Growing Profit Margin: REPL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: REPL is unprofitable, and losses have increased over the past 5 years at a rate of 36.7% per year.
Accelerating Growth: Unable to compare REPL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: REPL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: REPL has a negative Return on Equity (-49.81%), as it is currently unprofitable.